clinical trial · NCT06701305
A Study of Efinopegdutide in Healthy Obese Participants (MK-6024-015)
Merck Sharp & Dohme LLC·phase1·completed·n = 48
HealthyEfinopegdutidePlaceboAcetaminophen
brief summary
The goal of this study is to learn about the safety of efinopegdutide (MK-6024) and how well overweight healthy people tolerate it. Researchers also want to know what happens to efinopegdutide in a person's body over time when taken as a single dose (Part 1) or as multiple doses (Part 2). In addition, the study will assess the amount of acetaminophen in the blood after receiving different strength doses of efinopegdutide (Part 2 only).
started
Jun 13, 2024
primary completion
Feb 18, 2025
completion
Feb 18, 2025
last updated
Feb 26, 2025
official title
A Single and Multiple-Ascending Dose Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Efinopegdutide (MK-6024) in Otherwise Healthy Obese Participants and the Effect of Multiple Doses of Efinopegdutide on the Pharmacokinetics of Acetaminophen
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol